ArticleJAMA network open2026
Early-Onset Metastatic Colorectal Adenocarcinoma Incidence and Survival Among Patients Younger Than 50 Years.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: There is evidence of an increasing incidence of early-onset (EO) colorectal metastatic adenocarcinoma (mADC). There is no population-based study detailing the patterns over time of the epidemiologic characteristics and prognosis of EO colorectal mADC. Objective: To describe patterns in colorectal mADC incidence and survival according to metastatic characteristics among patients younger than 50 years compared with older patients. Design, Setting, and Participants: This population-based cohort study used data from the French Network of Cancer Registries (FRANCIM) on 37 297 individuals with a new diagnosis of invasive colorectal adenocarcinoma from January 1, 2004, to December 31, 2021. Statistical analysis was conducted from August to November 2025. Main Outcomes and Measures: Metastatic status was categorized into nonmetastatic disease, metastatic disease, single-site metastases, multiple-site metastases, liver metastasis, peritoneal metastasis, and lung metastasis. Incidence was modeled using a flexible multivariable Poisson model to estimate annual percentage changes according to metastatic characteristics. Net survival was estimated using the Pohar Perme estimator and a flexible cumulative hazard model. Results: Of the 37 297 individuals with a new diagnosis of invasive colorectal adenocarcinoma (mean [SD] age, 72.0 [12.2] years; 20 692 males [55.5%]), 1558 (4.2%) received a diagnosis before 50 years of age, and 9995 (26.8%) had mADC. The incidence of single-site metastases did not increase in any age class or sex, whereas the incidence of multiple-site metastases among patients aged 15 to 39 years increased annually by 9.5% (95% CI, 2.7%-16.7%) in males and 10.3% (95% CI, 3.4%-17.6%) in females. The increase in incidence in the EO mainly concerned the peritoneum and to a lesser extent the liver. The probability of presenting with peritoneal metastasis in 2021 was 6.2-fold higher than in 2004 among males aged 15 to 39 years. Net survival of mADC improved over time, except for peritoneal metastasis, and was consistently higher among patients aged 15 to 49 years than among those aged 50 to 75 years. Conclusions and Relevance: In this cohort study, the incidence of EO mADC increased mainly among patients with multiple metastatic sites and those with peritoneum rather than liver or lung involvement. Net survival improved over time except for peritoneal involvement. These results suggest that intensive treatment is needed for young adults with EO mADC when the peritoneum is involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.